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Introduction
•

•

•

Obstructive sleep apnea (OSA) is a common, yet serious condition1
– Repetitive nocturnal airway collapse, leading to cessation of breathing
– Associated with stroke, hypertension, arrhythmias, decreased cognitive
function, and diminished quality of life2
Diagnosis of OSA includes either a home or in-laboratory sleep study to establish
the extent of airway obstruction
– Study results will typically report an apnea-hypopnea index (AHI), denoting
severity of disease
– AHI – apnea and hypopnea events per hour
Effective first-line treatments of OSA include continued positive airway pressure
(CPAP) therapy or mandibular repositioning3
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Introduction
•

Following failure of CPAP or mandibular device,
several surgical manipulations for OSA treatment
exist
• Procedures selected depend on location of obstruction
and individual patient anatomy4

•

Currently, a standard of care does not exist for the anesthetic approach
utilized for OSA patients receiving surgery
•
•
•
•

Two highly utilized general anesthetic agents were evaluated in this study:
Total Intravenous Anesthesia (TIVA) and Sevoflurane Gas (SEVO)
Conflicting literature exists as to which method is superior
Meta-analyses have shown that TIVA leads to faster recovery times with
less postoperative nausea5
Potential impacts on efficiency and cost of recovery care, and patient
satisfaction

Objectives & Hypothesis
• Research Question: How does Total Intravenous Anesthesia (TIVA)
compare with Sevoflurane Gas (SEVO) with respect to resultant
postoperative experience and recovery time in OSA patients
undergoing surgery?

• Hypothesis: OSA patients undergoing surgery will experience
reduced postoperative nausea and faster recovery times following
administration of TIVA compared with patients that receive SEVO.

Approach & Results
•
•

•
•
•

•

Study design: Retrospective Cohort Study
Population: OSA patients undergoing corrective surgery (Jan. 2019-Dec
2019)
– Surgeries included nasal surgeries, uvulopalatopharyngoplasty
(UPPP) and upper airway stimulation (UAS)
– SEVO (n=86)
• Nasal (n=47)
• UAS (n=29)
• UPPP (n=10)
– TIVA (n=62)
• Nasal (n=24)
• UAS (n=30)
• UPPP (n=8)
Intervention: Administration of TIVA with propofol + remifentanil
Comparison: Outcomes of patients receiving SEVO
All data was obtained from Epic medical history charts
– Outcomes collected included time-based measures (total surgery and
anesthesia time, time to emergence, time to PACU phase I/II
completion, and total recovery time), incidence of postoperative
nausea
Rationale behind this approach:
– Retrospective review of patients with known anesthesia modality
– Appropriate time data was available to conclude if recovery times
differed
– Adverse events and complications occurring weeks later were also
obtainable with this approach
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Approach & Results
• Methods of analysis:
– Analyses were performed using Graphpad Prism software
using the following tests:
• Unpaired nonparametric Mann-Whitney U tests (time
comparisons/demographics)
• Fischer’s Exact tests (categorical data)
• Multiple linear regression (correlating OSA severity with recovery time)

Approach & Results
Demographics

SEVO Patients
(n=86)

TIVA Patients
(n=62)

P Value

Age

52.7 ± 11.2 years

55.4 ± 12.1 years

P=.1265

Sex

78% Males (n=67)
22% Females (n=19)

77% Males (n=48)
23% Females (n=14)

P=1.00

Race

78% Caucasian (n=67)
14% African American (n=12)
5% Hispanic (n=3)
6% Other (n=4)

91% Caucasian (n=56)
3% African American (n=2)
6% Hispanic (n=4)
0% Other (n=0)

P=.0737
P=.0433
P=.4530
P=.1426

BMI

31.1 ± 4.7 kg/m2

29.8 ± 3.6 kg/m2

P=.1424

AHI

31.6 ± 24.9

30.5 ± 18.9

P=.8848

OSA Severity
% Mild OSA
AHI ≥5 - <15
% Moderate OSA
AHI ≥15 - <30
% Severe OSA
AHI ≥30
Surgical Procedure
% Nasal Surgery
% Upper Airway Stimulation (UAS)
% Uvulopalatopharyngoplasty (UPPP)

24% Mild OSA (n=21)

19% Mild OSA (n=12)

P=.0774

34% Moderate OSA (n=29)

37% Moderate OSA (n=23)

P=.1247

42% Severe OSA (n=36)

44% Severe OSA (n=27)

P=.3585

55% Nasal (n=47)

39% Nasal (n=24)

34% UAS (n=29)

48% UAS (n=30)

12% UPPP (n=10)

13% UPPP (n=8)

P=.0672
P=.0893
P=.8051

Approach and Results
Median PACU phase I time decreased with TIVA across all surgical
subtypes. Total recovery decreased in all surgeries except UPPP.

UAS Median PACU phase I difference: 42.5 min (p<.001, 95% CI 20.00 - 61.00)
UPPP Median PACU phase I difference: 36 min (p=.022, 95% CI 6.00 - 83.00)
Nasal Median PACU phase I difference: 35.5 min (p<.001, 95% CI 18.00 - 52.00)

Approach and Results
Median PACU phase I time decreased with TIVA across all
severities of OSA with surgeries combined.

Mild Median PACU phase I difference: 23.5 min (p=.004, 95% CI 11.00 - 55.00)
Moderate PACU phase I difference: 52 min (p=.004, 95% CI 11.00 - 63.00)
Severe Median PACU phase I difference: 47 min (p<.001, 95% 16.00 - 56.00)

Approach and Results
Logarithmic 2-fold AHI increases correlates with increased
PACU phase I time in SEVO patients.

SEVO phase I time increase: 16.8 min (p<.001, 95% CI 9.2 to 22.4)
TIVA phase I time increase: 4.3 min (p=.489, 95% CI -7.9 to 16.5)

Approach and Results
Incidence of postoperative nausea and vomiting (PONV)
did not differ in cohorts based on anesthesia received.

SEVO
TIVA

PONV

No PONV

10

76

2

60

Fischer’s Exact Test of PONV Incidence: p=.07

Conclusions
• Based on this retrospective cohort:

– Surgical OSA patients experience reduced recovery time
with TIVA regardless of OSA severity or surgery received
– OSA patients receiving SEVO experience increased time
spent in recovery with increasing OSA severity
– Incidence of PONV did not differ based on anesthesia
received, but may do so with an increased sample size

• Overall, our findings of reduced recovery time after
TIVA are consistent with meta-analyses of the general
population5
• Implications of these findings may include improved
efficiency of care delivery and patient satisfaction, and
potentially reduced cost of recovery care
– Further studies are needed to confirm these impacts

Future Directions
• Extensions of this study include:
– Prospective RCT placing patients in either a TIVA or SEVO
group
• More thorough assessment of postoperative pain and
nausea
– Cost analysis of this cohort utilizing Jefferson financial data
and billing to insurance
– Assessment of TIVA vs. SEVO in non-OSA patients
undergoing otolaryngologic procedures (tonsillectomy,
rhinoplasty, facelift, etc.)
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